Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A specific MRI-detected pattern of brain atrophy may help predict how quickly patients with early-onset Alzheimer's disease (EOAD) progress from mild cognitive impairment (MCI) to dementia. In a longitudinal study of 130 patients, each standard deviation increase in cortical atrophy was linked to a 24% higher risk of progression. The MRI signature added meaningful prognostic value beyond standard clinical assessments alone.
One of the most common questions patients with early-onset Alzheimer's disease (EOAD) ask their doctors is: "When will I lose my independence?" A new study published in Neurology suggests an MRI-based brain atrophy signature could help answer that — at least in part.
Researchers studied 130 adults (mean age ~60) with biomarker-confirmed EOAD at the mild cognitive impairment (MCI) stage. Over roughly two years, 65% progressed to dementia. Those with greater baseline cortical atrophy in EOAD-vulnerable brain regions progressed significantly faster, and the MRI measure added prognostic value on top of age, sex, and clinical severity scores.
The tool isn't ready for routine clinical use yet — the cohort was predominantly non-Hispanic White and mostly amnestic MCI, limiting generalizability. Researchers plan to validate it across diverse populations and explore combining it with blood- and PET-based biomarkers.
Key Takeaways:
Why it matters: Better prognostic tools for EOAD could help patients and families plan ahead, guide monitoring schedules, and identify the optimal window for therapeutic intervention — a critical gap in current care.
